5/2/2014

GE Healthcare announced at the American Academy of Neurology annual meeting that its DaTscan tracer for use with SPECT brain imaging achieved an overall sensitivity of 91.9% and specificity of 83.6% when evaluated by onsite readers across four clinical trials and 88.7% sensitivity and 91.2% specificity under blind evaluation by independent experts. The tracer was used to detect striatal dopaminergic deficit, a condition linked to Parkinsonian syndromes.

Related Summaries